Rabah Ben Yaou,Pomi Yun,Ivana Dabaj,Gina Norato,Sandra Donkervoort,Hui Xiong,Andres Nascimento,Lorenzo Maggi,Anna Sarkozy,Soledad Monges,Marta Bertoli,Hirofumi Komaki,Michele Mayer,Eugenio Mercuri,Edmar Zanoteli,Claudia Castiglioni,Chiara Marini-Bettolo,Adele D'Amico,Nicolas Deconinck,Isabelle Desguerre,Ricardo Erazo-Torricelli,Juliana Gurgel-Giannetti,Akihiko Ishiyama,Karin S. Kleinsteuber,Emmanuelle Lagrue,Vincent Laugel,Sandra Mercier,Sonia Messina,Luisa Politano,Monique M. Ryan,Pascal Sabouraud,Ulrike Schara,Gabriele Siciliano,Liliana Vercelli,Thomas Voit,Grace Yoon,Rachel Alvarez,Francesco Muntoni,Tyler M. Pierson,David Gomez-Andres,A. Reghan Foley,Susana Quijano-Roy,Carsten G. Bonnemann,Gisele Bonne

Abstract:Muscular dystrophies due to heterozygous pathogenic variants in LMNA gene cover a broad spectrum of clinical presentations and severity with an age of onset ranging from the neonatal period to adulthood. The natural history of these conditions is not well defined, particularly in patients with congenital or early onset who arguably present with the highest disease burden. Thus the definition of natural history endpoints along with clinically revelant outcome measures is essential to establishing both clinical care planning and clinical trial readiness for this patient group. We designed a large international cross-sectional retrospective natural history study of patients with genetically proven muscle laminopathy who presented with symptoms before two years of age intending to identify and characterize an optimal clinical trial cohort with pertinent motor, cardiac and respiratory endpoints. Quantitative statistics were used to evaluate associations between LMNA variants and distinct clinical events. The study included 151 patients (median age at symptom onset 0.9 years, range: 0.0-2.0). Age of onset and age of death were significantly lower in patients who never acquired independent ambulation compared to patients who achieved independent ambulation. Most of the patients acquired independent ambulation (n = 101, 66.9%), and subsequently lost this ability (n = 86; 85%). The age of ambulation acquisition (median: 1.2 years, range: 0.8-4.0) and age of ambulation loss (median: 7 years, range: 1.2-38.0) were significantly associated with the age of the first respiratory interventions and the first cardiac symptoms. Respiratory and gastrointestinal interventions occurred during first decade while cardiac interventions occurred later. Genotype-phenotype analysis showed that the most common mutation, p.Arg249Trp (20%), was significantly associated with a more severe disease course. This retrospective natural history study of early onset LMNA-related muscular dystrophy confirms the progressive nature of the disorder, initially involving motor symptoms prior to onset of other symptoms (respiratory, orthopaedic, cardiac and gastrointestinal). The study also identifies subgroups of patients with a range of long-term outcomes. Ambulatory status was an important mean of stratification along with the presence or absence of the p.Arg249Trp mutation. These categorizations will be important for future clinical trial cohorts. Finally, this study furthers our understanding of the progression of early onset LMNA-related muscular dystrophy and provides important insights into the anticipatory care needs of LMNA-related respiratory and cardiac manifestations.

Clinical and molecular characterization of limb‐girdle muscular dystrophy 2G/R7 in a large cohort of Brazilian patients

Genetic profile of Brazilian patients with LAMA2‐related dystrophies

Myopathy due to carnitine palmitoyltransferase II deficiency: updating genetic aspects of the first publication in Brazil

Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil

Clinical Features and Molecular Genetic Analysis of a Pedigree of Limb Girdle Muscular Dystrophy

The clinical features and TCAP mutation Spectrum in a Chinese cohort of patients with limb-girdle muscular dystrophy R7

Detection of gene variants associated with recessive limb–girdle muscular weakness and Pompe disease in a global cohort of patients through the application of next-generation sequencing analysis

Clinical, Myopathological and Genetic Mutations Features of Limb Girdle Muscular Dystrophy 2I

Expert panel curation of 31 genes in relation to limb girdle muscular dystrophy

A Multicenter Cross-Sectional Study of the Swiss Cohort of LAMA2-Related Muscular Dystrophy

Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy

Identification of a founder effect involving n.197C>T variant in RMRP gene associated to cartilage-hair hypoplasia syndrome in Brazilian patients

Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study

International Retrospective Natural History Study of LMNA-related Congenital Muscular Dystrophy.

The importance of geographic and sociodemographic aspects in the characterization of mucopolysaccharidoses: a case series from Ceará state (Northeast Brazil)

Classic and Atypical Late Ingantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa

Disease progression in Sanfilippo type B: Case series of Brazilian patients

Spinocerebellar Ataxia in Brazil: A Comprehensive Genotype – Phenotype Analysis

Case report: A novel patient presenting TRIM32-related limb-girdle muscular dystrophy

In a cohort of 961 clinically suspected Duchenne muscular dystrophy patients, 105 were diagnosed to have other muscular dystrophies (OMDs), with LGMD2E (variant SGCB c.544A>C) being the most common

Gaucher disease in Brazil: a comprehensive 16 year retrospective study on survival, cost, and treatment insights